TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under regulation 30 of SEBI (LODR) regulation, 201512-06-2024
12-06-2024
Torrent Pharmaceuticals secured licensing agreement with Takeda, shares up
The Indian market for GERD treatments is valued at 8,064 crore, with an 8% CAGR over the last four years, based on AWACS MAT April 2024 data05-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India05-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call with Analysts / Investors on Audited Financial Results for the quarter and year ended 31st March, 202430-05-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Newspaper cuttings in connection with transfer of shares to IEPF.29-05-2024
Torrent Pharma Q4 Results Review - Another Quarter Of Strong Margins: Prabhdas Lilladher
Guided for $250-300 million US revenues in next three-five years.27-05-2024
Torrent Pharma Shares Hit Record On Post Result Target Price Hikes
Brokerage firm Citi has raised the stock's target price to Rs 3,000 from Rs 2,960 earlier while maintaining its 'buy' rating.27-05-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Resignation of Director
In continuation to our earlier letter dated 24-May-24 intimating the desire of Jinesh Shah to step down as the Director of the Company effective from 23-Jul-24, please find the letter attached herewith received from Jinesh Shah as Annexure 1 in this respect24-05-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
In continuation to our letter dated 10-May-24 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2024, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording31032024.mp324-05-2024
Torrent Pharmaceuticals Results Earnings Call for Q4FY24
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.24-05-2024